Monitoring and treatment disparities for youth on antipsychotics.

ANTIPSYCHOTIC agents; DRUG monitoring; HEALTH services accessibility; HEALTH status indicators; INSURANCE; MEDICAL prescriptions; METABOLIC disorders; RACE; OFF-label use (Drugs); INAPPROPRIATE prescribing (Medicine); DISEASE risk factors; ADOLESCENCE

The need for effective interventions in the management of neuropsychiatric conditions in youths has led to increased use of psychotropic medications, particularly antipsychotics. Several are approved by the Food and Drug Administration (FDA) for administration in youths to treat schizophrenia, bipolar disorder, autism‐related irritability, and Tourette's disorder. However, by and large, these medications are used off‐label to target dysregulated conduct or emotional features such as aggression (48% of treated symptoms), irritability (19%), and impulsivity (11%). Only 5% of prescriptions are for FDA‐approved indications. [ABSTRACT FROM AUTHOR]

Copyright of Brown University Child & Adolescent Behavior Letter is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)